Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

SpaceX plans to leverage its experience with the Starlink constellation for its proposed orbital data center constellation of up to one million satellites. Credit: SpaceX WASHINGTON — SpaceX is ...

Trump administration finalizes better-than-feared Medicare Advantage payment rate in boost to health insurers A family found a strange metal sphere in the woods. It started moving on its own—then the ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Function Health, a startup that offers lab testing and body scans for early disease detection, scored nearly $300 million in series B funding, boosting its valuation to $2.5 billion. Redpoint Ventures ...

Apurva Wadodkar, Sr. Director Data & AI at TI Automotive, is a data science leader driving strategic, people-first innovation at scale. Over the last two decades, I have had the chance to roll up my ...

The delayed release of the BLS report has led to fearmongering about the economy's ability to function. Leila Fadel, host of NPR's Up First, said on Friday that "businesses and policymakers are flying ...

Today, a brief rundown of news involving Insmed and Recursion Pharmaceuticals, as well as updates from Odyssey Therapeutics, Gilead Sciences and Novo Nordisk that you may have missed.